TVI Kidney 1
Alternative Names: TVI-Kidney-1Latest Information Update: 01 Feb 2023
At a glance
- Originator TVAX Biomedical
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Renal cell carcinoma
Most Recent Events
- 01 Feb 2023 Phase II development is still ongoing in Renal cell carcinoma in USA (TVAX Biomedical website, February 2023)
- 14 Dec 2020 Phase II trial is still ongoing in Renal cell carcinoma in USA (TVAX Biomedical website, December 2020)
- 14 Dec 2020 TVAX Biomedical has patent protection for its immunotherapy platform in the USA, Canada and in several European countries before December 2020 (TVAX Biomedical website, December 2020)